Your browser doesn't support javascript.
loading
Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria.
Graham, Jonathan; McBride, Doreen; Stull, Donald; Halliday, Anna; Alexopoulos, Stamatia Theodora; Balp, Maria-Magdalena; Griffiths, Matthew; Agirrezabal, Ion; Zuberbier, Torsten; Brennan, Alan.
Afiliação
  • Graham J; RTI Health Solutions, Research Triangle Park, NC, USA.
  • McBride D; RTI Health Solutions, Manchester, UK.
  • Stull D; RTI Health Solutions, Research Triangle Park, NC, USA.
  • Halliday A; Novartis Pharmaceuticals UK Limited, Frimley Business Park, Surrey, UK. anna.halliday@novartis.com.
  • Alexopoulos ST; Novartis Pharmaceuticals UK Limited, Frimley Business Park, Surrey, UK.
  • Balp MM; Novartis Pharma AG, Basel, Switzerland.
  • Griffiths M; Costello Medical Consulting Ltd, Cambridge, UK.
  • Agirrezabal I; Costello Medical Consulting Ltd, Cambridge, UK.
  • Zuberbier T; Department of Dermatology and Allergy, Allergy-Centre-Charité, Charité-University Hospital Berlin, Berlin, Germany.
  • Brennan A; University of Sheffield, Sheffield, UK.
Pharmacoeconomics ; 34(8): 815-27, 2016 08.
Article em En | MEDLINE | ID: mdl-27209583
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation / Prognostic_studies Limite: Adult / Humans País/Região como assunto: Europa Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation / Prognostic_studies Limite: Adult / Humans País/Região como assunto: Europa Idioma: En Ano de publicação: 2016 Tipo de documento: Article